LLY’s sell-off today is driven by underwhelming data from its new oral GLP‑1 drug—but it came on the heels of an otherwise stellar earnings report and outlook upgrade. If you believe in Lilly’s leadership in obesity and diabetes treatments, its strong cash flows, and long-term drug development pipeline, this could be a compelling opportunity to buy at a discount.
Rare discount at 15% below the monthly average with a price last seen in Feb 2024. Buy the dip back to $700s.
Rare discount at 15% below the monthly average with a price last seen in Feb 2024. Buy the dip back to $700s.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.